1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds
Authors:
- 1 May 2014
- journal article
- research article
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 7 (5) , 482-493
Abstract
No abstract availableKeywords
Funding Information
- Abbott Vascular
This publication has 32 references indexed in Scilit:
- Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes MellitusCirculation, 2011
- Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery DiseaseNew England Journal of Medicine, 2010
- Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysisBMJ, 2008
- Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery DiseaseJAMA, 2008
- effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patientsJACC, 2002
- Outcomes in diabetics undergoing revascularizationJACC, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention TrialDiabetes Care, 1993